Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methadone Conversion Ratios in Cancer Pain
NCT01836328Phase 3
Key facts
- Status
- Completed
- Start
- Aug 2011
- Primary completion
- Jun 2015
- Countries
- 1
- Sponsor
- L'Hospitalet de Llobregat
- Modality
- Orthosteric Ligands
- Drugs
- methadone
- Conditions
- cancer pain
01
Overview
Phase 3, randomised, single-blind trial of methadone in cancer pain (2 arms), sponsored by L'Hospitalet de Llobregat. Primary endpoint: Proportion of intoxicated patients at 3 days. Started Aug 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Ratio 1:2
Parenteral to oral methadone conversion ratio 1:2
Ratio 1:1.2
Parenteral to oral methadone conversion ratio 1:1.2
03
Who it enrols
Adult patients with advanced cancer and pain controlled by parenteral methadone for 48 hours without significant toxicity.
04
Endpoints
Primary
Proportion of intoxicated patients
Secondary
Parenteral/oral MTD final ratio in patients considered as failure
Beyond the preview
Go deeper on NCT01836328.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836328.